Rain Therapeutics Inc
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Rain Therapeutics Inc is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which they are able to genetically select patients they believe will most likely benefit. Its lead product candidate, RAIN-32 is a small molecule, oral inhibitor of mouse double minute 2, which is oncogenic in numerous cancers.
Latest RAIN News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News